Sinuses of Valsalva
SoV · PLAX, end-diastole, leading-edge to leading-edge (echo convention); maximum sinus-to-sinus on CT/CMR
Normal range & thresholds
Men 34 ± 3 mm · Women 30 ± 3 mm.[1] Practical upper limits ≈40 mm (men) and ≈36 mm (women); indexed ≈19 mm/m². Because size tracks body size and age, a diameter should be read against a height- and BSA-based nomogram (Z-score >2 = dilated) rather than a single number, particularly in the very tall, very short, and under 40s.[9,18]
Pathophysiology
Cystic medial degeneration — elastic-fibre fragmentation, proteoglycan accumulation and smooth-muscle apoptosis — reduces wall tensile strength. Laplace’s law then makes dilatation self-accelerating: wall stress rises with radius, so a wider sinus generates more stress, which drives more dilatation. TGF-β signalling is the shared final pathway in Marfan and Loeys-Dietz; in bicuspid valves, eccentric systolic jets add abnormal wall shear stress.[9,10]
Raised by
- Marfan syndrome (classic root-predominant pattern), Loeys-Dietz, vascular Ehlers-Danlos
- Familial thoracic aortic aneurysm — often normal habitus, positive family history
- Bicuspid aortic valve, root phenotype (≈20–25% of BAV aortopathy)
- Chronic severe aortic regurgitation and long-standing hypertension
- Aortitis: Takayasu, giant cell, syphilitic, IgG4-related, ankylosing spondylitis
- Isolated congenital sinus of Valsalva aneurysm — asymmetric, one sinus only, may rupture into RA/RV
- Turner syndrome (index to BSA — absolute diameter looks falsely reassuring)
Lowered by
- Not a meaningful finding. A small root is constitutional.
- Apparent shrinkage on serial studies is almost always a convention or plane change, not regression — verify before reporting reassurance.
Technique & pitfalls
- End-diastole, PLAX, leading-edge to leading-edge perpendicular to the long axis (ASE echo convention); CT and CMR use inner-edge to inner-edge at end-diastole, and the two differ by 2–4 mm.[9,18]
- Always name the convention and the modality in the report; serial comparison is only valid within one convention.
- Sweep the probe up and down one interspace: the maximum sinus diameter is often missed on the single standard cut.
- In doubt, measure sinus-to-sinus and sinus-to-commissure on a true short-axis (CT) — TTE sees only one pair of sinuses.
- Report the four levels separately (annulus / sinuses / STJ / ascending). ‘Aortic root 42 mm’ without a level is uninterpretable.
Pseudo-change & artefact
- Convention mismatch is the single commonest cause of apparent interval growth: echo LE-LE vs CT IE-IE.
- Oblique PLAX cuts the root tangentially and overestimates by several mm.
- Non-ECG-gated CT motion artefact can both overestimate diameter and mimic a dissection flap.
- Systolic instead of end-diastolic frame adds 1–3 mm.
- Inter-observer variability is ±2–3 mm — growth below this on a single repeat study is noise, which is why guidelines demand growth over consecutive studies.
Treatment thresholds
- 2022 ACC/AHA: root or ascending ≥5.5 cm → surgery (class I) in sporadic tricuspid-valve aortopathy; ≥5.0 cm (class IIa) in a high-volume centre with a multidisciplinary aortic team.[9]
- Marfan: ≥5.0 cm class I; ≥4.5 cm if rapid growth, family history of dissection, or planned pregnancy. Loeys-Dietz / high-risk genotype: 4.0–4.5 cm depending on variant.[9]
- Growth rate: ≥0.5 cm in 1 year, or ≥0.3 cm/year over 2 consecutive years → surgery (class IIa).[9]
- Body-size indexed triggers: cross-sectional area (cm²) / height (m) >10 → class IIa.[9]
- Concomitant surgery: when the patient is already having AVR or other cardiac surgery, replace the root/ascending aorta at ≥4.5 cm (class IIa).[9]
- 2024 EACTS/STS: ≥55 mm class I; ≥52 mm class IIa at low operative risk; BAV root phenotype ≥50 mm; BAV ascending phenotype >50 mm with age <50 y, short stature or growth >3 mm/year.[10]
Next step
- Next: confirm with ECG-gated CTA or MRA — TTE alone must not carry a surgical decision.[9]
- Then: assess the valve (BAV? AR severity? STJ effacement?) and screen the whole aorta to the bifurcation.
- Then: genetic testing and first-degree-relative imaging if age <60 y, syndromic features, or family history of aneurysm/dissection (class I).[9]
- Surveillance: <4.5 cm and stable → annually; 4.5–5.0 cm or growing → 6-monthly; pair every echo with periodic cross-sectional imaging.
Drugs
- Beta-blockers (target heart rate <70/min) reduce dP/dt and are standard in Marfan.
- ARBs (losartan) reduce TGF-β signalling; combined with beta-blockade in syndromic aortopathy.
- BP target <130/80 mmHg (class I) in all thoracic aortic disease.[9]
- Avoid fluoroquinolones; counsel against isometric straining and stimulant use.[9]
Reversibility
0%. A dilated sinus never returns to normal — the medial matrix is destroyed, not stunned. All medical therapy does is slow the growth rate (roughly 30–50% slowing in Marfan trials, with the beta-blocker/ARB comparison still debated). The only restoration is surgical: valve-sparing root replacement or a composite graft.[9,10]